The Chicago Police Department has announced that it will use LRAD Corp.'s (LRAD-NASDAQ) long-range acoustic devices (LRAD) to communicate to crowds during the 2012 NATO Summit in Chicago. This is one of many safety and security measures the city has put in place in preparation for the event, which begins Sunday, May 20, 2012. Various protests and demonstrations are expected leading up to and throughout the Summit.
The Chicago Police Department sought improved techniques to ensure that orders can be effectively delivered to crowds and protestors. Just this morning, a federal court judge gave preliminary approval to a $6 million+ settlement to protestors who were arrested by Chicago police after police failed to give clear orders to protestors during an anti-war march nearly a decade ago. Chicago Police have purchased two LRAD units to clearly communicate messages to crowds at the upcoming Summit.
LRAD Corp.'s products have also been used for public safety at the G20 Summit in Pittsburgh during 2009 and the Occupy Wall Street movement in New York and Los Angeles in late 2011.
Long Range Acoustic Device® (LRAD®) Platform
The LRAD® platform uses directionality and focused acoustic output to support communication over distances of 10 meters to 8,900 meters. Similar to a spotlight, which produces an intense beam of light directly onto a subject, each LRAD® system delivers a focused directional audio broadcast. The beam width, frequency range, and maximum continuous output of LRAD® devices ensures intelligible communication over both distance and loud background noise, and can be adjusted to target individuals, small groups, or large crowds. By placing sound only where needed, LRAD® improves upon traditional speaker systems and adds novel sound applications that conventional technologies have been unable to achieve.
The Company’s product line meets a broad range of requirements for communicating to and deterring potential threats, from the hand-held LRAD 100X™ to the permanently installed LRAD 2000X™. To the Company’s knowledge, each LRAD® model presents the loudest and most intelligible AHD in its size and weight category.
Each LRAD® device is capable of delivering live voice broadcasts through an attached microphone, and both voice broadcasts and deterrent tones using a hardened MP3 player. Messages can be recorded and saved for later use in multiple languages, which can improve communication in situations where a language barrier is present. Moreover, various bird calls and predator tones can be recorded to prevent wildlife from approaching a potentially dangerous area (e.g., wind farms, airports, or waste areas).
LRAD® can be combined with a number of features (e.g., radar, cameras) that further improve communication and interaction. There is also an option to operate the device remotely across an Internet Protocol (IP)-accessible network. Whereas traditional security and sensor networks allow a user to view a location in real-time, LRAD® enables a first responder capability—allowing the user to communicate to an individual in real time. For example, in a security scenario where LRAD® is operated remotely, command and control center officials could communicate directly to an individual before they breach a secure perimeter, which could alter the individual’s behavior and potentially prevent that person from entering the area. Moreover, LRAD® can be deployed in nearly any type of environment. The rugged, lightweight, and waterproof casing of LRAD® meets the stringent requirements of the U.S. military—ensuring that the device can be operated in harsh environments while also remaining portable. Figure 3 demonstrates the durability of an LRAD® system.
As of February 2012, LRAD® systems had been deployed in approximately 45 countries across North America, Europe, Asia, Africa, Europe, and Australia.
Additional information about the Company's products and technologies is provided in Crystal Research Associates' 64-page Executive Informational Overview® on LRAD Corp.
May 15, 2012 (CNW), LAVAL, QC--
BELLUS Health Inc. (BLU-TSX) ("BELLUS Health" or the "Company") conducted its Annual and Special Meeting of Securityholders in relation to the $17.25 million strategic transaction and financing with Pharmascience Inc. announced on April 5, 2012. The Company also reported its financial results for the first quarter ended March 31, 2012, and provided a corporate update.
Corporate Highlights
- Securityholders have voted in favor of the $17.25 million strategic partnership and financing with Pharmascience, which is expected to close by May 25, 2012.
- 90 patients have been enrolled in the Company's Phase III confirmatory trial for KIACTA™ in AA amyloidosis.
- Preliminary, blinded data from the 78 patients profiled in the Phase III trial demonstrates that demographics and baseline characteristics are very similar to the previous trial.
- Exclusive license and distribution agreement was signed with LevPharm Ltd. for VIVIMIND™ in Israel.
Summary of Financial Results
All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
- For the three-month period ended March 31, 2012, net loss amounted to $3,193,000, or ($0.01) per share, versus a net income of $3,299,000, or ($0.01) per share, for the corresponding period the previous year. The increase in net loss in the current quarter is mainly attributable to a decrease in finance income period over period, as explained below.
- Revenues amounted to $568,000 for the three-month period ended March 31, 2012, compared to $746,000 for the corresponding period the previous year. Revenues mainly consist of revenue from the asset sale and license agreement as well as the service agreement entered into with Celtic Therapeutics in 2010 for KIACTA™.
- Research and development expenses, net of research tax credits and grants, amounted to $329,000 for the three-month period ended March 31, 2012, compared to $811,000 for the corresponding period the previous year. The decrease is mainly attributable to a reduction in expenses incurred in relation to NRM8499 Phase I clinical trial for the treatment of Alzheimer's disease, which ended in the first quarter 2011, and a reduction in the workforce and other cost reduction initiatives implemented by the Company during the past year.
- General and administrative expenses amounted to $1,278,000 for the three-month period ended March 31, 2012, compared to $1,096,000 for the corresponding period the previous year. Expenses in 2011 are net of a gain on sale lease back of $1,176,000 in relation to the lease of the Company's Laval, Quebec, premises that was terminated in April 2011. Excluding this item, the decrease is mainly due to a reduction in the workforce and other cost reduction initiatives implemented by the Company during the past year.
- Finance income amounted to $734,000 for the three-month period ended March 31, 2012, compared to $6,356,000 for the corresponding period the previous year. The decrease is primarily related to finance income recorded in 2011 in relation to the decrease in the fair value of the embedded conversion option liability on the 2009 Notes in the amount of $6,067,000. The conversion option of the 2009 Notes is considered as an embedded derivative that should be marked to market through income.
- Finance costs amounted to $2,888,000 for the three-month period ended March 31, 2012, compared to $1,896,000 for the corresponding period the previous year. The increase is primarily related to finance costs recorded in 2012 in relation to the increase in the fair value of the embedded conversion option liability on the 2009 Notes in the amount of $667,000. The increase is also due to the increasing accretion expense recorded on the 2009 Notes as they advance to maturity.
Financial Position and Going Concern
As at March 31, 2012, the Company had available cash and cash equivalents of $4,107,000, compared to $5,105,000 as at December 31, 2011. As at March 31, 2012, the Company's cash and cash equivalents on hand and expected sources of funds are considered, in management's view, to be sufficient to meet its committed cash obligations and expected level of expenditures over the next 12 months.
Should the transaction with Pharmascience be completed, whereby Pharmascience will pay a total of $17.25 million to BELLUS Health, it will remove the going concern material uncertainty for the foreseeable future.
Please view the original press release for additional information about the Pharmascience partnership and financing, the VIVIMIND™ license and distribution agreement, AA Amyloidosis, as well as BELLUS Health's forward-looking statement disclosure.
SOURCE: BELLUS Health Inc.
May 15, 2012 (Marketwire), SAN DIEGO, CA--
LRAD Corp. (LRAD-NASDAQ) announced it has received a $1.7 million LRAD-RX systems order for Asian maritime security. Deliveries on the order are scheduled to begin this quarter and continue into the Company's 2013 fiscal year.
"This order further confirms that our LRAD-RX systems are becoming an important component in maritime escalation of force (EOF) protocols to help combat terrorist and piracy threats," stated Tom Brown, president and CEO of LRAD Corporation. "When a suspicious vessel fails or refuses to respond to radio calls, the LRAD-RX initiates the EOF through powerful voice broadcasts and deterrent tones. By unequivocally determining the intent of an approaching threat, the LRAD-RX assists armed security forces to avoid accidental shooting incidents while providing them time and distance to scale their response and make life and death decisions."
The Company's proprietary LRAD-RX (shown below) features a camera, high intensity searchlight (optional), a robust, IP-addressable full pan and tilt drive for precise aiming and tracking, and can be integrated with radar to provide automated vessel alerts. The LRAD-RX broadcasts highly intelligible, hails, warnings and instructions over distances up to 2 miles. Through the use of focused, multi-language voice commands and deterrent tones, the LRAD-RX creates increased standoff zones, determines intent, supports peaceful conflict resolution, and potentially prevents the use of deadly force.
"Our LRAD® systems have proven to be highly effective for maritime security," Brown added. "To date, LRAD systems have helped to prevent accidental shooting incidents and to peacefully resolve hundreds of maritime EOF situations throughout the world."
About LRAD Corporation
LRAD Corp. is using long-range communication to resolve uncertain situations peacefully and save lives on both sides of its proprietary Long Range Acoustic Device®. Thousands of LRAD® systems are in service around the world in diverse applications including fixed and mobile military deployments, maritime security, critical infrastructure and perimeter security, commercial security, border and port security, law enforcement and emergency responder communications, asset protection, and wildlife preservation and control.
For more information about the Company and its LRAD systems, please visit http://www.crystalra.com/research-library/lrad-corp/.
May 15, 2012 (BUSINESS WIRE), CAMBRIDGE, Mass.--
InVivo Therapeutics Holdings Corp. (NVIV-OTC.BB) reported financial results for the three months ended March 31, 2012 (summarized below), and provided a business update.
Recent Corporate Highlights
- Biopolymer Scaffolding Scheduled to Enter Clinical Studies for Spinal Cord Injury (SCI) in 2012. InVivo expects to commence a pilot human clinical trial during the second half of 2012, pending approval of an Investigational Device Exemption (IDE) application by the FDA. Following a meeting with the FDA held in April, the Company is expecting the product to be regulated under the Humanitarian Use Device/Humanitarian Device Exemption (HUD/HDE) pathway that should accelerate commercialization. The pilot study will be an open-label study and is designed to evaluate the safety and efficacy in SCI patients following treatment with the biopolymer scaffolding. This study follows promising preclinical studies completed in non-human primates. InVivo is the first to successfully demonstrate functional improvement in non-human primates that were paralyzed after an SCI model.
- Submissions to be Filed with the FDA for Injectable Hydrogel to Treat Peripheral Nerve Injuries and SCI. InVivo is conducting a preclinical study with Geisinger Health System to evaluate the Company’s injectable biocompatible hydrogel for the treatment of pain caused by peripheral nerve compression. Approximately 3.2 million pain injections are performed annually to treat back, neck, and leg pain caused by peripheral nerve injuries. InVivo’s hydrogel is designed to time-release anti-inflammatory drugs for extended pain relief. The product addresses an estimated $15 billion market for peripheral nerve injuries. InVivo expects to file FDA applications during 2012 for the use of the injectable hydrogel to treat peripheral nerve injuries and SCI.
- Raised $20mm of Equity Capital. In February 2012, InVivo completed a $20mm public offering led by a select group of institutional investors. Net proceeds to InVivo were approximately $18.1mm. InVivo also has the potential to receive an additional $18.6mm of capital from the exercise of previously issued outstanding warrants.
- Key Additions to the Management Team. InVivo recently announced the appointments of Jack Harvey, formerly of Pervasis, as senior director of manufacturing, Brian Hess, formerly of Stryker, as director of product development, and Celina Chang, formerly of Pervasis, as senior scientist. Under the leadership of new chief science officer, Edward Wirth, M.D., Ph.D., InVivo has established a foundation for the further advancement of chronic SCI technologies.
- New Global Headquarters: InVivo has signed a multi-year lease for a 21,000 square-foot facility at One Kendall Square in Cambridge, Massachusetts. The new state-of-the-art facility will bring all of the Company’s operations under one roof and will house corporate offices, a vivarium, laboratory space, and a cGMP clean room for manufacturing.
Financial Results
For the three months ended March 31, 2012, the Company reported net income of $3,150,000 or ($0.05) per diluted share, compared to a net loss of $1,278,000, or ($0.02) per diluted share, for the three months ended March 31, 2011. Included in results for the three months ended March 31, 2012 and 2011 were non-cash derivative gains of $5,613,000, and $121,000, respectively, reflecting decreases in the fair value of the derivative warrant liability. Exclusive of the non-cash derivative gain, the pro forma net loss for the three months ended March 31, 2012, was $2,463,000, or ($0.04) per diluted share, compared to a pro forma net loss of $1,399,000, or ($0.03) per diluted share for 2011.
Total operating expenses for the three months ended March 31, 2012, were $2,461,000 compared with $1,401,000 for the three months ended March 31, 2011. The Company's cash balance increased to $19.6mm at March 31, 2012, from $4.4mm at December 31, 2011. In February 2012, InVivo completed a $20mm public offering and issued 9,523,810 shares of common stock at a price to the public at $2.10 per share. Net proceeds to InVivo were approximately $18.1mm.
Please see the original press release for financial tables as well as InVivo's Safe Harbor Statement.
* Greater details about the $20mm public offering are provided in InVivo's Form 10-Q filed May 14, 2012.
SOURCE: InVivo Therapeutics Holdings Corp.
As researchers have recently emphasized, governments have a significant role and responsibility for providing long-term support for renewable energy, smart grid, and other future “sustainable city” initiatives. The price of renewable energies and associated technologies are too high to appeal to investors without government support. Mechanisms such as incentives, feed‐in‐tariffs, tax‐breaks, rebates, and other financial instruments are critical.
With that in mind, we have released a 12-page report that expands upon several U.S. policies expected to further market adoption of sustainable, nanotechnology-driven technologies. The report, Continuing Coverage of Nanotechnology and the Built Environment (available here), is the latest update to our base report, Nanotechnology and the Built Environment: The Transition to Green Infrastructure. This update is part of a series of “continuing coverage” reports from Crystal Research Associates that detail innovations in nanotechnology and their impact on our infrastructure, building, and construction markets.
Included in the report are discussions of the following, among other topics:
-
U.S. building code changes may open opportunities for building‐integrated photovoltaics (BIPV).
-
The U.S. Department of Energy (DOE) is emphasizing industrial energy assessments for manufacturing facilities, and industrial assessment centers at universities—to date, such assessments have helped save over 530 trillion British Thermal Units (BTUs) of energy (enough to meet the needs of 5.5 million homes) and have helped manufacturers save more than $5.6 billion in energy costs.
-
The DOE is now pitching a long‐term vision for the U.S. electricity system to state regulators, with emphasis on three central themes: (1) a seamless system from generation to end use; (2) support of clean energy; (3) a system to empower consumers by providing more choices. Under this vision, the DOE hopes to easily integrate any form of energy generation or storage into the main infrastructure as well as make it easy for outsiders to offer new products, services, and markets.
-
President Obama’s 2013 energy budget request targets efficiency and renewable energy investment.
-
President Obama announces funding for alternative fuel technologies that is designed to capitalize on the nearly 100‐year supply of American natural gas. The DOE is also supporting development of transportation fuels from algae, and is currently backing more than 30 algae‐based biofuels projects. Algae‐derived biofuels have the potential to replace up to 17% of the U.S.’s imported oil for transportation.
In addition to the policy news, all of our nanotechnology updates provide readers with highlights and pertinent trends from the key sectors benefitting from advanced technologies and green investment.
The March 2012 update also includes sector developments from…
Cement/Concrete ▪ Display Technologies ▪ Lighting/Organic Light‐emitting Diodes (OLEDs) ▪ Nanomaterials ▪ Smart Grid Networks ▪ Water Treatment ▪ Windows
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2012--
InVivo Therapeutics Holdings Corp. (NVIV-OTC.BB) announced the appointment of Jack Harvey as senior director of manufacturing and Celina Chang as senior scientist as the Company ramps up preparations for a human clinical trial and begins to expand its product portfolio to other nervous system conditions.
“InVivo is at an inflection point in our growth, and adding industry leaders like Mr. Harvey and Ms. Chang will take our platform technology in new directions. We are creating a new paradigm in the treatment of neurological injuries, and as our team evolves we are pleased that we continue to attract the best in our business, enabling us to expedite our products to market.”
~ Frank Reynolds, Chief Executive Officer
Jack Harvey, Senior Director of Manufacturing
Mr. Harvey will lead InVivo Therapeutics’ production of GMP polymer-based biomaterial technologies. Leveraging his seven years as the director of manufacturing at Pervasis Therapeutics, Inc., where he led combination biomaterial and cell therapy products through the FDA, Mr. Harvey will lend his knowledge to InVivo’s existing and future product pipeline. He will manage contracted and internal resources as well as chemistry, manufacturing, and control (CMC) development and manufacturing scale up. Mr. Harvey received a B.A. in biology from Harvard University and a M.P.H. Health Law from Boston University, School of Public Health.
“I’m excited to lead InVivo’s optimization of GMP biomaterial technology manufacturing processes,” Mr. Harvey said. “Spinal cord injury treatments are a very promising field, and I’m eager to provide patients with viable solutions for SCI and other nervous system disorders.”
Celina Chang, Senior Scientist
Ms. Chang previously worked at Pervasis as a scientist charged with process improvement for the company’s three-dimensional polymer matrix embedded with cells. At InVivo, Ms. Chang will lead the execution and review of experiments per GMP and GLP regulations, and undertake the analysis of various cultured cells for InVivo’s chronic spinal cord injury therapies. Prior to Pervasis, Ms. Chang worked at Ortec International, focused on advancing regenerative medicine and stem cell therapies. She holds a B.S. in biological engineering from Cornell University.
“We strongly believe that combination therapies are the future of chronic spinal cord injury, and I look forward to developing these technologies,” said Ms. Chang.
About InVivo Therapeutics Holdings Corp.
InVivo is a medical device company seeking to commercialize improved treatments for spinal cord injuries (SCIs) that use innovative biomaterials to restore function. InVivo estimates that up to 90% of patients with an acute SCI are in spinal shock immediately following a traumatic injury but are not permanently paralyzed. It is often the secondary injuries that occur in response to the trauma—bleeding, inflammation, and scarring—that lead to paralysis. Thus, InVivo aims to improve the prognosis of SCI patients by helping the spinal cord heal itself before secondary damages, including paralysis, take effect. To do so, InVivo has developed a medical device composed of a resorbable biopolymer, which is a type of biomaterial used extensively in the medical field for tissue engineering. InVivo’s scaffold device is designed for implantation or injection into the damaged spinal cord as a complement to the standard screw-rod procedure performed when an SCI patient is admitted to the hospital. The scaffold functions to protect the spinal cord and promote neuroplasticity in the remaining healthy tissue. As well, the scaffolds can be a vehicle for the controlled delivery of anti-inflammatory pharmaceuticals and regenerative cell therapies directly to the injury site. This technology, based on several decades of research at MIT’s Langer Lab, has shown efficacy in preclinical studies. It is expected to enter clinical trials during the second half of 2012 and be regulated as a Class III medical device.
Greater information about InVivo and its product portfolio is provided in Crystal Research Associates' 56-page Executive Informational Overview (EIO).
The details in this press release are governed by InVivo's Safe Harbor Statement available here.
ANN ARBOR, Mich., May 11, 2012 /PRNewswire/ --
Synthetic Biologics, Inc. (SYN-NYSE Amex), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that to improve its corporate governance and strengthen the Board, it has split the roles of Chairman and Chief Executive Officer, and appointed Jeffrey J. Kraws to serve as its independent, non-executive Chairman of the Board. Mr. Kraws has served on the Company's Board of Directors since January 2006, and will continue to serve on the Compensation and Nominations Committees.
Mr. Kraws is Chief Executive Officer and co-founder of Crystal Research Associates. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a "5-Star Rating" in 2001 by Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research Associates in 2003, Mr. Kraws served as co-president of The Investor Relations Group, a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Co.). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. He holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo.
"We congratulate Jeff on his appointment as independent Chairman of the Synthetic Biologics' Board. This important step strengthens Synthetic Biologics' corporate governance practices," stated Jeffrey Riley, Chief Executive Officer, President and Director of the Board at Synthetic Biologics. "Jeff's life science experience will be instrumental in guiding our business and strategic development initiatives."
Upon his appointment Mr. Kraws stated, "I look forward to working closely with Jeff as the Company continues to build its pipeline of synthetic DNA-based therapeutics and innovative medicines for serious illnesses. Transitioning the Chairman role to an independent board member should allow our CEO and his management team to focus on the operations of the Company, with the ultimate objective of increasing value for our shareholders."
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia, and amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
Please see the full press release for Synthetic Biologics' forward-looking statement disclosure.
SOURCE: Synthetic Biologics, Inc.
MONTGOMERYVILLE, Pa.--(BUSINESS WIRE)--May 10, 2012--
PhotoMedex, Inc. (PHMD-NASDAQ) reported financial results for the three months ended March 31, 2012. Financial highlights of the 2012 first quarter include:
- Revenues of $50.3 million, an increase of 45% compared with the prior-year first quarter and an increase of 75% sequentially
- Consumer revenues of $42.2 million, an increase of 26% compared with the prior-year first quarter and an increase of 63% sequentially
- Gross profit of $39.0 million, an increase of 37% or $10.5 million compared with the first quarter of 2011
- Gross margin of 77.7% compared with 82.1% in the prior-year first quarter, reflecting the inclusion of revenues from the pre-merged PhotoMedex
- Income before taxes, litigation expense and one-time expenses of $7.8 million, net income of $4.9 million
- Litigation and one-time expenses of $2.7 million
- Adjusted income of $10.7 million or $0.56 per diluted share
On December 13, 2011, Radiancy, Inc. became a majority owned subsidiary of PhotoMedex in a reverse merger. In accordance with generally accepted accounting principles (GAAP), Radiancy is deemed to be the financial acquirer for financial statement purposes and therefore the related consolidated statements of operations for the periods prior to December 31, 2011, do not include activity from the pre-merged PhotoMedex prior to the date of merger.
Reported Financial Results
Revenues for the first quarter 2012 were $50.3 million, an increase of 45% over the same period last year. Included in this amount is $7.1 million in revenues from pre-merged PhotoMedex. This compares with revenues for the first quarter 2011 of $34.7 million, which included no revenues from pre-merged PhotoMedex.
Net income for the first quarter of 2012 was $4.9 million, or $0.26 per diluted per share, which included $1.8 million in stock-based compensation expense, $1.3 million in depreciation and amortization expenses, $1.8 million in litigation expenses, and $0.5 million in other one-time charges. This compares with net income for the first quarter 2011 of $8.1 million, or $0.68 per diluted share, which included $0.1 million in stock-based compensation expense, $0.1 million in depreciation and amortization expenses and $0.7 million in litigation expenses.
As of March 31, 2012, the Company had cash and cash equivalents of $23.5 million. On April 27, 2012, the Company raised $40.0 million in gross proceeds from concurrent registered offerings of 3,023,432 shares of Common Stock, yielding net proceeds of $37.8 million.
On a pro forma basis, had the merger been completed on January 1, 2011, revenues for the three months ended March 31, 2011, would have been $42.9 million, gross profit would have been $32.1 million, and net income would have been $6.3 million.
About PhotoMedex, Inc.
PhotoMedex is a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians, and consumers. The company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer), and photo damage. Its experience in the physician market provides the platform to expand its skin health solutions to spa markets, as well as traditional retail, online, and infomercial outlets for home-use products. As a result of its December 2011 merger with Radiancy Inc., PhotoMedex has added a range of home-use devices under the no!no!™ brand, for various indications including hair removal, acne treatment, and skin rejuvenation. The company also offers a professional product line for acne clearance, skin tightening, psoriasis care, and hair removal sold to physician clinics and spas.
Greater information about PhotoMedex and its product portfolio is provided in Crystal Research Associates' 60-page Executive Informational Overview (EIO).
PhotoMedex's Financial statements, Safe Harbor Statement, and other information is provided in the original press release.
MedPro Safety Products, Inc. (MPSP-OTC.BB) and Unilife Corporation (UNIS-NASDAQ) were featured in the May 2012 edition of Drug Development & Delivery in an article, entitled "Prefilled Syringes - A Container of Choice for Pharma." Drug Development & Delivery interviewed leading players in the prefilled syringe market to learn about their products and how each company is addressing pharma’s needs for safety, ease of use, cost, and product differentiation.
The full issue is available online at Drug Development & Delivery, May 2012. MedPro and Unilife are profiled on pages 38-40.
London-based business information company Visiongain expects the global prefilled syringe market to reach $3.9 billion in 2015 (up from $2.7 billion in 2012), fueled by improved performance, product stability, convenience of use, and cost-effectiveness.
MedPro Safety Products, Inc. (MPSP-OTC.BB)
MedPro develops safer medication delivery and blood collection systems. The company licenses, develops, and manufactures transformational technologies, which are then marketed through global medical device partners. MedPro’s products address multiple product categories within the medication delivery and blood collection markets. Unlike many competitive products available on the market, MedPro’s products incorporate safety features that operate without user activation, and therefore require little or no clinician training to use. Visit www.medprosafety.com or http://www.crystalra.com/research-library/medpro-safety/ for additional information about MedPro and its product portfolio.
Unilife Corporation (UNIS-NASDAQ)
Unilife is a developer and commercial supplier of advanced drug delivery systems. The company reports that its Unifill syringe is the world's first and only prefilled syringe with fully integrated safety features. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms, including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems, and specialized devices for targeted organ delivery. Visit www.unilife.com or http://www.crystalra.com/research-library/unilife-corporation/ for greater details about Unilife and its various advanced drug delivery systems.
About Drug Development & Delivery
Drug Development & Delivery presents the latest scientific and business information in drug development for professionals working in Research & Development, Business Development, Product Life-Cycle Management, and Corporate Management. The magazine has approximately 20,000 subscribers.
Yesterday, T3 Motion, Inc. (TTTM-NYSE Amex) announced that the Israeli government has awarded T3 Motion and its Israeli distributor, Yaum Ltd., a two-year contract for T3 Series Electric Stand-up Vehicles (ESV). The T3 ESV is now the default personal mobility vehicle for all Israeli government agencies.
The decision was made based on the results from a trial performed to measure the effectiveness of various ESVs in multiple cities throughout Israel, including Haifa, Netanya, Ashdod, and Tel Aviv.
The T3 Series ESV is a high-performance vehicle capable of speeds of up to 20 mph. The T3 Series has a zero-degree turning radius for improved maneuverability and a cargo capacity of 450 pounds. This vehicle can access restricted spaces, including elevators and narrow corridors, handle curbs, and deliver a quiet, emission-free operation. A raised, nine-inch standing platform provides the rider with an elevated vantage point to evaluate any situation, while making the public aware of the ESV’s presence. To date, over 3,000 T3 Series vehicles have been deployed in over 30 countries globally.
| T3 Series Electric Stand-up Vehicles (ESV) |
 |
Among other benefits, the T3 Series ESV is intended to enhance the effectiveness and efficiency of law enforcement patrols, allowing officers to respond to calls faster and with lower physical exertion. Its open-air design also improves officers’ approachability, allowing for interaction with the community that may enhance police agencies’ community relations and perception.
In addition to operational efficiencies, deploying the T3 Series may save money due to lower operating and maintenance costs versus gasoline-powered vehicles. According to T3 Motion’s customers’ calculations, assuming an average distance of 15 to 20 miles daily, the cost to recharge a T3 Series ESV is less than $0.10 a day—an equivalent of over 500 miles per gallon. Ultimately, the use of a T3 Series ESV can translate into an annual operating savings of $17,500 to $24,500 per gasoline-powered vehicle replaced, yielding a return on investment (ROI) timeframe of approximately seven months.
Follow Crystal Research on Facebook or Twitter to be among the first to receive updates and announcements on T3 Motion's latest development initiatives.